The results of clinical trials conducted in the US regarding the AstraZeneca vaccine are known.
About 32,000 people participated in the study. Most were from the US, although individuals from Chile and Peru were also involved in the survey.
It was found that the vaccine protects the human body from the virus by 79% and from the development of severe forms by 100%.
Studies have shown that the vaccine does not pose a threat to human health and does not cause thromboembolism.
The results of the study may have an impact on European countries that have stopped using AstraZeneca.
It is noteworthy that some European countries have already resumed using the Oxford vaccine after regulatory agencies published a report on the safety.
The World Health Organization calls on countries to use the AstraZeneca vaccine.
Earlier, the World Health Organization (WHO) team of experts concluded that a thrombus association with the AstraZeneca coronavirus vaccine was not confirmed. According to them, the benefits of the vaccine outweigh the risks.
On March 18, the European Medicines Agency gave the green light to the AstraZeneca vaccine. The head of the European Medicines Agency said the AstraZeneca vaccine was a safe and effective choice.
